A Mario Marcondes

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. pmc Inhibition of IL-32 activation by α-1 antitrypsin suppresses alloreactivity and increases survival in an allogeneic murine marrow transplantation model
    A Mario Marcondes
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 118:5031-9. 2011
  2. pmc No telomere shortening in marrow stroma from patients with MDS
    A Mario Marcondes
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Ann Hematol 88:623-8. 2009
  3. pmc The helix-loop-helix transcription factor TWIST is dysregulated in myelodysplastic syndromes
    Xiang Li
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 116:2304-14. 2010
  4. pmc Transcriptional regulation of miR-10a/b by TWIST-1 in myelodysplastic syndromes
    Xiang Li
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Haematologica 98:414-9. 2013
  5. pmc Stroma-dependent apoptosis in clonal hematopoietic precursors correlates with expression of PYCARD
    Andrew J Mhyre
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 113:649-58. 2009
  6. pmc Identification of DJ-1/PARK-7 as a determinant of stroma-dependent and TNF-alpha-induced apoptosis in MDS using mass spectrometry and phosphopeptide analysis
    A Mario Marcondes
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 115:1993-2002. 2010
  7. pmc α-1-Antitrypsin (AAT)-modified donor cells suppress GVHD but enhance the GVL effect: a role for mitochondrial bioenergetics
    A Mario Marcondes
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA Division of Oncology, University of Washington, Seattle, WA
    Blood 124:2881-91. 2014
  8. pmc The KDM2B- let-7b -EZH2 axis in myelodysplastic syndromes as a target for combined epigenetic therapy
    Ekapun Karoopongse
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
    PLoS ONE 9:e107817. 2014
  9. pmc Allogeneic transplantation, Fas signaling, and dysregulation of hepcidin
    Xiang Li
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 19:1210-9. 2013
  10. pmc Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function
    A Mario Marcondes
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Department of Pathology, and Division of Oncology, University of Washington, Seattle, WA 98195
    Proc Natl Acad Sci U S A 105:2865-70. 2008

Collaborators

Detail Information

Publications10

  1. pmc Inhibition of IL-32 activation by α-1 antitrypsin suppresses alloreactivity and increases survival in an allogeneic murine marrow transplantation model
    A Mario Marcondes
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 118:5031-9. 2011
    ..04). These findings suggest that AAT modulates immune and inflammatory functions and may represent a novel approach to prevent or treat GVHD...
  2. pmc No telomere shortening in marrow stroma from patients with MDS
    A Mario Marcondes
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Ann Hematol 88:623-8. 2009
    ....
  3. pmc The helix-loop-helix transcription factor TWIST is dysregulated in myelodysplastic syndromes
    Xiang Li
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 116:2304-14. 2010
    ..These data suggest role for dysregulation of TWIST in the pathophysiology of MDS. Conceivably, TWIST or components in the signaling pathway could serve as therapeutic targets for patients with MDS...
  4. pmc Transcriptional regulation of miR-10a/b by TWIST-1 in myelodysplastic syndromes
    Xiang Li
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Haematologica 98:414-9. 2013
    ..These data support a role for miR10a/10b in the regulation of apoptosis in myelodysplastic syndrome and suggest the TWIST-1/miR10a/b-axis as a therapeutic target in myelodysplastic syndrome...
  5. pmc Stroma-dependent apoptosis in clonal hematopoietic precursors correlates with expression of PYCARD
    Andrew J Mhyre
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 113:649-58. 2009
    ..These data indicate that stroma may convey not only protective effects on hematopoietic cells, but, dependent upon the milieu, may also facilitate apoptosis...
  6. pmc Identification of DJ-1/PARK-7 as a determinant of stroma-dependent and TNF-alpha-induced apoptosis in MDS using mass spectrometry and phosphopeptide analysis
    A Mario Marcondes
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 115:1993-2002. 2010
    ..18). These data suggest that DJ-1/p53 interactions contribute to apoptosis resistance in clonal myeloid cells and may serve as a prognostic marker in patients with MDS...
  7. pmc α-1-Antitrypsin (AAT)-modified donor cells suppress GVHD but enhance the GVL effect: a role for mitochondrial bioenergetics
    A Mario Marcondes
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA Division of Oncology, University of Washington, Seattle, WA
    Blood 124:2881-91. 2014
    ..1(+) cells, CD4(+)CD25(+)FoxP3(+) T cells, and CD11c(+) DCs but not for effector T cells, suggesting a cell type-specific effect of AAT. Thus, via altered metabolism, AAT exerts effective GVHD protection while enhancing GVL effects...
  8. pmc The KDM2B- let-7b -EZH2 axis in myelodysplastic syndromes as a target for combined epigenetic therapy
    Ekapun Karoopongse
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
    PLoS ONE 9:e107817. 2014
    ..DZNep might be able to enhance the therapeutic effects of DNA hypomethylating agents such as 5-azacitidine, currently considered standard therapy for patients with MDS...
  9. pmc Allogeneic transplantation, Fas signaling, and dysregulation of hepcidin
    Xiang Li
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 19:1210-9. 2013
    ..These data indicate that Fas-dependent signals alter the regulation of iron homeostasis and suggest that signals initiated by Fas may contribute to peritransplantation iron accumulation. ..
  10. pmc Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function
    A Mario Marcondes
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Department of Pathology, and Division of Oncology, University of Washington, Seattle, WA 98195
    Proc Natl Acad Sci U S A 105:2865-70. 2008
    ..We propose that IL-32 is a marrow stromal marker that distinguishes patients with MDS and CMML. Furthermore, IL-32 appears to contribute to the pathophysiology of MDS and may be a therapeutic target...